# Venus Remedies (NSE: VENUSREM) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/VENUSREM · Pivot · prices to 30 Sep 2026

Venus Remedies (NSE: VENUSREM) closed at ₹1,796.10 on 30 Sep 2026. With a market capitalisation of ₹2,401 Cr, it ranks 1058th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 23.3× trailing earnings, against a return on equity of 15.5% in FY26. Over the past year the share price has risen 293.9%. Its 52-week range is ₹428.00 (30 Sep 2025) to ₹2,044.30 (29 Jun 2026); the last close is 12.1% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹179 Cr (+35.6% year on year) and net profit ₹23 Cr (+139.3%), on a consolidated basis. Promoters held 41.76% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹1,796.10 |
| Market cap | ₹2,401 Cr |
| P/E (trailing) | 23.3 |
| ROE | 15.5% (FY26) |
| ROCE | 19.4% (FY26) |
| Debt to equity | 0 |
| 52-week high | ₹2,044.30 (29 Jun 2026) |
| 52-week low | ₹428.00 (30 Sep 2025) |
| 1-year return | +293.9% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹179 Cr | +35.6% | ₹23 Cr | +139.3% | ₹17.18 |
| Q4 FY26 | ₹259 Cr | +33.0% | ₹47 Cr | +126.1% | ₹35.53 |
| Q3 FY26 | ₹180 Cr | +1.9% | ₹26 Cr | +30.5% | ₹19.14 |
| Q2 FY26 | ₹193 Cr | +15.1% | ₹20 Cr | +471.9% | ₹15.06 |
| Q1 FY26 | ₹132 Cr | +21.4% | ₹10 Cr | +686.9% | ₹7.18 |
| Q4 FY25 | ₹195 Cr | −0.1% | ₹21 Cr | +99.8% | ₹15.71 |
| Q3 FY25 | ₹177 Cr | +23.3% | ₹20 Cr | +186.1% | ₹14.66 |
| Q2 FY25 | ₹167 Cr | −0.2% | ₹4 Cr | −64.6% | ₹2.63 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹648 Cr | ₹45 Cr |
| FY24 | ₹601 Cr | ₹28 Cr |
| FY23 | ₹556 Cr | ₹27 Cr |
| FY22 | ₹599 Cr | ₹41 Cr |
| FY21 | ₹548 Cr | ₹62 Cr |
| FY20 | ₹339 Cr | −₹10 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 41.76%
- Foreign institutions: 2.92%
- Domestic institutions: 0.89%
- Non-institutions: 54.43%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Dishman Pharma](https://app.pivotnow.in/stock/DPC02) | — | ₹2,676 Cr | — | — |
| [Hikal](https://app.pivotnow.in/stock/HIKAL) | ₹210.01 | ₹2,589 Cr | — | — |
| [Dr Agarwals Eye Hospital](https://app.pivotnow.in/stock/DRAGARWQ) | ₹5,025.00 | ₹2,428 Cr | — | — |
| [Alembic](https://app.pivotnow.in/stock/ALEMBICLTD) | ₹92.33 | ₹2,371 Cr | 7.5 | — |
| [Fredun Pharmace](https://app.pivotnow.in/stock/FREDUN) | ₹1,376.10 | ₹2,276 Cr | 22.5 | — |
| [Dishman Carbogen Amcis](https://app.pivotnow.in/stock/DCAL) | ₹141.95 | ₹2,226 Cr | 22.8 | — |

## Questions and answers

### What is the share price of Venus Remedies today?

Venus Remedies (NSE: VENUSREM) last closed at ₹1,796.10 on 30 Sep 2026. Its 52-week high is ₹2,044.30 and its 52-week low is ₹428.00.

### What is the market cap of Venus Remedies?

Venus Remedies' market capitalisation is ₹2,401 Cr (₹2,401 Cr) at the 22 Oct 2026 close, ranking 1058th among the NSE companies Pivot tracks.

### What is the P/E ratio of Venus Remedies?

Venus Remedies trades at a trailing P/E of 23.3. The median P/E of the 3 closest Pharma & Healthcare peers by market cap is 22.5.

### What is the ROE and ROCE of Venus Remedies?

Return on equity was 15.5% in FY26 and return on capital employed was 19.4% in FY26 (consolidated figures).

### Is Venus Remedies a debt-free company?

Venus Remedies is close to debt-free: its debt-to-equity ratio was 0 in FY26.

### What were Venus Remedies' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Venus Remedies reported revenue of ₹179 Cr, +35.6% year on year, and net profit of ₹23 Cr, +139.3% year on year.

### How has Venus Remedies stock performed over the last year?

Venus Remedies' share price has risen 293.9% over the past year, +2.6% over three months and +8.2% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Venus Remedies?

As of 30 Jun 2026: promoters 41.76%, foreign institutions 2.92%, domestic institutions 0.89%, non-institutions 54.43%.

### Who are Venus Remedies' competitors?

The listed Pharma & Healthcare companies closest to Venus Remedies by market cap are Dishman Pharma, Hikal, Dr Agarwals Eye Hospital, Alembic, Fredun Pharmace and Dishman Carbogen Amcis.

### Is Venus Remedies a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Venus Remedies' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on VENUSREM against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.